People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2015 |
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2014 |
| Enobia Pharma Corp | — | Biotechnology | Series C | $100.0M | $819.2M | 2009 |
| Arteaus Therapeutics, LLC | — | Biotechnology | Series B | $19.2M | $619.2M | 2011 |
Thomas Schuetz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Schuetz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Silverstein | 2 | 10 |
| Carl Gordon | 1 | 24 |
| Jean-Francois Formela | 1 | 17 |
| Jonathan Leff | 1 | 11 |
| Kush Parmar | 1 | 10 |
| Ben Auspitz | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Errik Anderson | 1 | 8 |
| Thomas Woiwode | 1 | 7 |
| Philip Ferneau | 1 | 6 |
| Philip J. Ferneau | 1 | 6 |
| David Grayzel | 1 | 6 |
| David Bonita | 1 | 6 |
| Eric L. Trachtenberg | 1 | 4 |
| Jeffrey Mack | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Steve Tregay | 1 | 2 |
| Louis Lange | 1 | 2 |
| Steve Squinto | 1 | 2 |
| Jonathan Sheller | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.